OABI News & Events

OmniAb expects 2026 revenue to be in the range of $25 million to $30 million, and costs and operating expenses to be in the range of $80 million to $85 million. Cash costs and operating expenses is expected to be in the range of $50 million to $55 million.

Reports Q4 revenue $8.4M, consensus $9.0M. "OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, several later-stage assets are emerging with potential to generate meaningful milestones and, ultimately, recurring royalty revenue," said Matt Foehr, Chief Executive Officer of OmniAb. "Our focus on innovation was evident in the recent launch of OmniUltra(TM), which strengthens our ability to attract new partners and service new programs. Additionally, we continue to see strong interest in the xPloration partner access program and are excited about its contributions to the business."

Virtual Meeting to be held to announce the company launches its new product, OmniUltra on December 15 at 5 pm hosted by Craig-Hallum.

OmniAb signied a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG, a joint venture between ArrowMark and Viking Global Investors. OmniAb will receive revenue for services performed as well as potential equity and royalties for the discovery of novel antibodies for targets defined by Mabtrx. ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. Founded in 1999, Viking Global Investors is a global investment firm with a long-term, fundamental, research-intensive approach to investing. Viking manages over $55B of capital across public and private investments.